Caroline Palm Apergi

Publications
Public outreach and news

Articles

Article: BLOOD CANCER JOURNAL. 2023;13(1):139

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia.

Shah K; Nasimian A; Ahmed M; Al Ashiri L; Denison L; Sime W; Bendak K; Kolosenko I; Siino V; Levander F; Palm-Apergi C; Massoumi R; Lock RB; Kazi JU
Article: METHODS IN MOLECULAR BIOLOGY. 2022;2383:257-264

Protein Delivery by PTDs/CPPs.

Palm-Apergi C; Dowdy SF
Article: FASEB JOURNAL. 2021;35(7):e21741

Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.

Goroshchuk O; Kolosenko I; Kunold E; Vidarsdottir L; Pirmoradian M; Azimi A; Jafari R; Palm-Apergi C
Article: FASEB JOURNAL. 2021;35(5):e21476

RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.

Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund A-C; Dowdy SF; Palm-Apergi C
Journal article: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020;20:s163

ALL-166: Novel RNAi Prodrugs Targeting Plk1 Induce Specific mRNA Cleavage in Pediatric Acute B-Cell Lymphoblastic Leukemia

Goroshchuk O; Vidarsdottir L; Björklund A-C; Hamil A; Kolosenko I; Dowdy S; Palm-Apergi C
Article: SCIENTIFIC REPORTS. 2020;10(1):2688

Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients.

Goroshchuk O; Vidarsdottir L; Björklund A-C; Hamil AS; Kolosenko I; Dowdy SF; Palm-Apergi C
Article: SCIENTIFIC REPORTS. 2019;9(1):536

STAT3 is activated in multicellular spheroids of colon carcinoma cells and mediates expression of IRF9 and interferon stimulated genes.

Edsbäcker E; Serviss JT; Kolosenko I; Palm-Apergi C; De Milito A; Tamm KP
Article: METHODS IN MOLECULAR BIOLOGY. 2019;2036:53-72

Designing siRNA and Evaluating Its Effect on RNA Targets Using qPCR and Western Blot.

Vidarsdottir L; Goroshchuk O; Kolosenko I; Palm-Apergi C
Article: NUCLEIC ACID THERAPEUTICS. 2017;27(5):260-271

Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers.

Hagopian JC; Hamil AS; van den Berg A; Meade BR; Eguchi A; Palm-Apergi C; Dowdy SF
Article: JOURNAL OF CONTROLLED RELEASE. 2017;261:199-206

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

Kolosenko I; Edsbäcker E; Björklund A-C; Hamil AS; Goroshchuk O; Grandér D; Dowdy SF; Palm-Apergi C
Article: PLOS ONE. 2017;12(6):e0178844

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.

Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
Article: NATURE BIOTECHNOLOGY. 2014;32(12):1256-1261

Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.

Meade BR; Gogoi K; Hamil AS; Palm-Apergi C; van den Berg A; Hagopian JC; Springer AD; Eguchi A; Kacsinta AD; Dowdy CF; Presente A; Lönn P; Kaulich M; Yoshioka N; Gros E; Cui X-S; Dowdy SF
Article: NATURE COMMUNICATIONS. 2011;2:453

Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides.

Lättig-Tünnemann G; Prinz M; Hoffmann D; Behlke J; Palm-Apergi C; Morano I; Herce HD; Cardoso MC
Article: METHODS IN MOLECULAR BIOLOGY. 2011;683:339-347

PTD-DRBD siRNA delivery.

Palm-Apergi C; Eguchi A; Dowdy SF
Article: METHODS IN MOLECULAR BIOLOGY. 2011;683:157-164

Calcium and membrane repair.

Palm-Apergi C; Hällbrink M
Article: FASEB JOURNAL. 2009;23(1):214-223

The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake.

Palm-Apergi C; Lorents A; Padari K; Pooga M; Hällbrink M
Article: JOURNAL OF CONTROLLED RELEASE. 2008;132(1):49-54

A new rapid cell-penetrating peptide based strategy to produce bacterial ghosts for plasmid delivery.

Palm-Apergi C; Hällbrink M
Article: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2007;1768(7):1769-1776

Peptide degradation is a critical determinant for cell-penetrating peptide uptake.

Palm C; Jayamanne M; Kjellander M; Hällbrink M
Article: PEPTIDES. 2006;27(7):1710-1716

Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects.

Palm C; Netzereab S; Hällbrink M

All other publications

Editorial comment: BLOOD. 2023;142(23):1941-1942

PLK4, a potential target against AML.

Palm-Apergi C
Editorial comment: FUTURE MEDICINAL CHEMISTRY. 2020;12(16):1457-1460

Small-molecule inhibitors for targeting polo-like kinase 1.

Kolosenko I; Palm-Apergi C
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020;20:S163

Novel RNAi Prodrugs Targeting Plk1 Induce Specific mRNA Cleavage in Pediatric Acute B-Cell Lymphoblastic Leukemia

Goroshchuk O; Vidarsdottir L; Bjorklund A-C; Hamil A; Kolosenko I; Dowdy S; Palm-Apergi C
Review: ONCOGENE. 2019;38(1):1-16

Polo-like kinases and acute leukemia.

Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
Editorial comment: MOLECULAR THERAPY. 2012;20(4):695-697

Do cell-penetrating peptides actually "penetrate" cellular membranes?

Palm-Apergi C; Lönn P; Dowdy SF

Articles

All other publications

News from KI

Events from KI